FDA clears Novartis' Promacta for pediatric ITP; Mylan's independent Dutch foundation brings on Lazard;

@FiercePharma: AB Science struggles to break out as canine cancer drug flounders. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Mylan recalls more injected cancer drugs it made for #Pfizer at its Agila plants in India. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Big Data study flags 'fairly compelling' link between stomach blockbusters and heart risks. Report | Follow @CarlyHFierce

> The FDA has cleared Novartis' ($NVS) Promacta for pediatric ITP patients. Report

> Mylan's ($MYL)  independent Dutch foundation named Lazard as its financial adviser, a step that could help it play a more active role as generics rival Teva ($TEVA) pursues a takeover. More

> In a new analysis of a Phase III study, Novartis' Xolair improved the quality of life by 78% for chronic spontaneous urticaria patients. Release

> Charity Médecins Sans Frontières appealed to India on Thursday not to give in to pressure to make it easier for large drugmakers to get patents in the country, potentially blocking the production of cheap generics. More

Medical Device News

@FierceMedDev: Illumina teams up with Chinese genomics firm for noninvasive prenatal test development. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Boston Scientific touts improved spinal cord stimulator at neuromodulation conference. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: FDA slaps Insulet with warning letter over insulin pumps. Article | Follow @EmilyWFierce

> Boston Scientific touts improved spinal cord stimulator at neuromodulation conference. Story

> Philips cautions on cardio mortality after ResMed sleep apnea data, intros cardiac imaging tool. Article

Biotech News

@FierceBiotech: Turns out drugmakers don't tell the whole truth about FDA rejections. More | Follow @FierceBiotech

@JohnCFierce: This will be a biotech to watch: Unum hits the gas on next-gen CAR-T tech after banking $65M round. Story | Follow @JohnCFierce

@DamianFierce: Listen to two arguably well-informed people talk about the week in biopharma. FierceBiotech Radio | Follow @DamianFierce

> GlaxoSmithKline's new asthma drug gets a split vote from FDA advisers. Report

> Microbiome startup Seres bags a 'breakthrough' tag on the way to a $100M IPO. Story

> Agios' top cancer drug notches more remissions on the way to Phase III. Article

And Finally... Overweight and obese women face an increased risk of developing breast cancer after menopause, a new analysis says. More

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.